ObjectiveTo detect the expression level of FBXO22 gene in bone marrow cells of patients with acute myeloid leukemia (AML), and analyze its correlation with clinical indications.
MethodsA total of 92 AML cases were collected, including 41 cases in the primary group, 28 cases in the complete remission (CR) group, 23 cases in the partial remission (PR) group, and 30 cases with renal anemia and iron deficiency anemia in the control group.The relative expression of FBXO22 mRNA in bone marrow cells was detected by real-time fluorescence quantitative PCR.The correlation between the expression of FBXO22 mRNA and the patient's gender, age, blood routine parameters and clinical classification of patients were analyzed in the primary group.
ResultsThere was a statistically significant difference in the expression level of FBXO22 mRNA among patients in each group (P<0.01).The levels of FBXO22 mRNA in the PR group and primary group were lower than those in the control group and CR group (P<0.05), but there was no statistically significant difference between the control group and CR group, PR group and primary group (P>0.05).There was significant difference in the expression level of FBXO22 mRNA among patients with different platelet counts in the primary group (P<0.05).Correlation analysis showed that there was a significant positive correlation between the platelet count and the relative expression level of FBXO22 mRNA in the primary group (r=0.492, P<0.01).
ConclusionsThe expression of FBXO22 in bone marrow of patients with AML is decreased, and positively associates with platelet count.
DownLoad: